查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1700171

2032 年泌尿道癌市场预测：按癌症类型、诊断技术、治疗、最终用户和地区进行的全球分析

Urinary Tract Cancer Market Forecasts to 2032 - Global Analysis By Cancer Type (Bladder Cancer, Urethral Cancer and Ureteric & Renal Pelvic Cancer), Diagnostic Technique, Treatment, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球泌尿道癌市场预计在 2025 年达到 37 亿美元，到 2032 年将达到 114 亿美元，预测期内的复合年增长率为 17.2%。

泌尿道癌是一种发生在负责产生和排泄尿液的器官（例如肾臟、输尿管、膀胱和尿道）的恶性肿瘤疾病。最常见的是膀胱癌，其次是肾臟癌和输尿管癌。它通常是由导致细胞不受控制地生长的基因突变引起的，并且常常受到吸烟、长期接触有毒化学物质、慢性发炎和遗传易感性等因素的影响。症状包括尿液中带血（血尿）、频尿、排尿疼痛和下腹部不适。

根据美国癌症协会预测，到2022年，将有超过1,800万美国人患有癌症病史。据估计，2024年美国将诊断出超过200万例新癌症病例。

免疫疗法和标靶治疗的采用率增加

泌尿道癌盛行率的不断上升加速了创新治疗方法的采用，特别是免疫疗法和标靶治疗。这些先进的治疗方法透过特异性针对癌细胞同时最大限度地减少对健康组织的损害来提高疗效。此外，随着临床试验和新型治疗剂研究的持续进行，肿瘤精准医疗的范围也不断扩大。对个人化治疗策略的日益关注预计将推动泌尿道癌市场的显着成长。

治疗费用高且难以取得

治疗泌尿道癌的费用仍然是一个重大障碍，特别是在医疗基础设施不发达的中低收入国家。免疫疗法和分子标靶药物等先进治疗方法价格昂贵，因此大部分患者无法负担。缺乏广泛的报销政策进一步加剧了挑战，限制了患者获得新疗法的机会。因此，儘管医学取得了进步，但经济限制仍然是市场扩张的主要障碍。

新的微创手术技术

外科肿瘤学技术的进步促进了治疗泌尿道癌症的微创手术的发展，改善了患者的治疗效果。与传统开放性手术相比，腹腔镜和机器人辅助手术等技术可以减少术后併发症、缩短住院时间并加快恢復时间。此外，对微创和患者友善治疗方法的需求不断增长，使得这一领域成为市场参与者的有利可图的成长机会。

标靶治疗药物抗药性的可能性

泌尿道癌市场面临的主要挑战之一是抗药性的出现，这会显着降低标靶治疗的有效性。随着时间的推移，癌细胞会形成适应性机制来逃避治疗效果，导致病情进展和治疗选择受限。新药配方成本高昂以及核准流程冗长是额外的障碍，使情况进一步复杂化，并对市场成长和病患生存构成严重威胁。

COVID-19的影响：

COVID-19 疫情严重影响了癌症的诊断和治疗，导致筛检、选择性手术和临床试验的延迟。封锁和重新分配医疗资源以管理 COVID-19 病例导致常规肿瘤护理中断，造成诊断延迟和预后不良。然而，这场大流行加速了远端医疗和远端患者监护的采用，改善了咨询和后续观察的机会。展望未来，医疗保健提供者将致力于加强癌症护理基础设施，以防止将来发生类似的中断。

预计经尿道肿瘤切除术将成为预测期内最大的手术

由于对微创手术解决方案的需求不断增长，预计经尿道肿瘤切除术领域将在预测期内占据最大的市场占有率。 TURT 已被广泛用于膀胱癌的诊断和治疗，具有恢復时间更短、併发症发生率更低、患者预后改善等优点。此外，膀胱癌復发率高，需要再次手术，进一步推动了市场的成长。

放射线治疗领域预计将在预测期内实现最高复合年增长率

在先进治疗技术需求的推动下，放射治疗领域预计将在预测期内达到最高成长率。强度调控放射治疗(IMRT) 和影像导航放射治疗(IGRT) 等创新技术提高了精确度、减少了对周围组织的损伤并改善了患者的治疗效果。此外，血尿和纤维化等放射线引起的副作用需要后续观察，这增加了对支持治疗的需求。

占比最大的地区：

在预测期内，由于患者人数迅速增加和医疗保健基础设施不断改善，预计亚太地区将占据最大的市场占有率。中国、印度和日本等国家泌尿道癌发病率的上升推动了对先进诊断和治疗解决方案的需求。此外，大型製药公司对肿瘤学研究的投资不断增加以及具有成本效益的学名药的推出也促进了市场扩张。

复合年增长率最高的地区：

在预测期内，北美预计将呈现最高的复合年增长率，这得益于精准医疗的进步、免疫疗法的采用率不断提高以及研究投资的增加。此外，支持快速药品核准和报销政策的强有力的法律规范正在促进市场成长。由于人口老化和生活方式相关的风险因素，泌尿道癌的盛行率不断上升，进一步推动了对先进疗法的需求。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球泌尿道癌市场（依癌症类型）

  • 膀胱癌
    • 移行细胞癌
    • 鳞状细胞癌
    • 腺癌
  • 尿道癌
  • 尿道癌/肾盂癌

6. 全球泌尿道癌市场（依诊断技术）

  • 膀胱镜检查
  • 经尿道肿瘤切除术
  • 影像检查
  • 尿液检查
  • 其他诊断技术

7. 全球泌尿道癌市场：治疗

  • 化疗
  • 膀胱内治疗
  • 放射治疗
  • 外科手术
  • 免疫疗法

8. 全球泌尿道癌市场（依最终用户）

  • 医院
  • 专科诊所
  • 门诊手术中心
  • 癌症研究所

9. 全球泌尿道癌市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Amgen Inc.
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genzyme Corporation
  • IkerChem SL
  • Kyowa Hakko Kirin Co
  • Medical Enzymes AG
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Shionogi & Co., Ltd
  • Spectrum Pharmaceuticals
  • Exact Sciences
  • ImmunityBio, Inc
Product Code: SMRC29074

According to Stratistics MRC, the Global Urinary Tract Cancer Market is accounted for $3.7 billion in 2025 and is expected to reach $11.4 billion by 2032 growing at a CAGR of 17.2% during the forecast period. Urinary Tract Cancer is a condition with malignant growths that develop in the organs responsible for urine production and excretion, including the kidneys, ureters, bladder, and urethra. The most common type is bladder cancer, followed by renal (kidney) cancer and ureteral cancer. It typically arises due to genetic mutations that cause uncontrolled cell growth, often influenced by factors like smoking, prolonged exposure to harmful chemicals, chronic inflammation, and genetic predisposition. Symptoms may include blood in the urine (hematuria), frequent urination, pain during urination, and lower abdominal discomfort.

According to the American Cancer Society, over 18 million Americans were reported to have a history of cancer in the year 2022. It is estimated that over 2 million new cancer cases are expected to be diagnosed in the United States in 2024.

Market Dynamics:

Driver:

Increasing adoption of immunotherapy and targeted therapies

The rising prevalence of urinary tract cancer has accelerated the adoption of innovative treatment approaches, particularly immunotherapy and targeted therapies. These advanced treatment modalities offer improved efficacy by specifically targeting cancer cells while minimizing damage to healthy tissues. Furthermore, ongoing clinical trials and research into novel therapeutic agents continue to expand the scope of precision medicine in oncology. The increasing focus on personalized treatment strategies is expected to drive significant growth in the urinary tract cancer market.

Restraint:

High treatment costs and limited accessibility

The cost of treatment for urinary tract cancer remains a significant barrier, particularly in low- and middle-income countries where healthcare infrastructure is underdeveloped. Advanced therapies such as immunotherapy and targeted drugs come with high price tags, making them unaffordable for a large portion of the patient population. The lack of widespread reimbursement policies further exacerbates the challenge, limiting patient access to novel therapies. As a result, financial constraints continue to be a major impediment to market expansion despite medical advancements.

Opportunity:

Emerging minimally invasive surgical techniques

Technological advancements in surgical oncology have led to the development of minimally invasive procedures for the treatment of urinary tract cancer, improving patient outcomes. Techniques such as laparoscopic and robotic-assisted surgeries offer reduced post-operative complications, shorter hospital stays, and faster recovery times compared to traditional open surgeries. Furthermore, as the demand for less invasive and patient-friendly treatment options rises, this segment presents a lucrative growth opportunity for market players.

Threat:

Potential drug resistance to targeted therapies

One of the major challenges in the urinary tract cancer market is the emergence of drug resistance, which can significantly reduce the effectiveness of targeted therapies. Over time, cancer cells develop adaptive mechanisms that enable them to evade the effects of treatment, leading to disease progression and limited therapeutic options. The high costs and lengthy approval processes for new drug formulations pose additional hurdles, further complicating the landscape posing a significant threat to market growth and patient survival rates.

Covid-19 Impact:

The COVID-19 pandemic had a profound impact on cancer diagnosis and treatment, causing delays in screenings, elective surgeries, and clinical trials. Lockdowns and healthcare resource reallocation toward managing COVID-19 cases led to disruptions in routine oncology care, resulting in late-stage diagnoses and poorer prognoses. However, the pandemic also accelerated the adoption of telemedicine and remote patient monitoring, improving access to consultations and follow-ups. Moving forward, healthcare providers are focusing on strengthening cancer care infrastructure to prevent similar disruptions in the future.

The transurethral resection of tumor segment is expected to be the largest during the forecast period

The transurethral resection of tumor segment is expected to account for the largest market share during the forecast period owing to driving demand for minimally invasive surgical solutions. TURT is widely adopted for diagnosing and treating bladder cancer, offering advantages such as reduced recovery time, lower complication rates, and improved patient outcomes. Moreover, high recurrence rates of bladder cancer necessitate repeat procedures, further boosting market growth.

The radiation therapy segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the radiation therapy segment is predicted to witness the highest growth rate driving demand for advanced treatment technologies. Innovations like intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) enhance precision, reducing damage to surrounding tissues and improving patient outcomes. Moreover, radiation-induced side effects, such as hematuria and fibrosis, necessitate follow-up care, boosting demand for supportive treatments.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its rapidly expanding patient population and improving healthcare infrastructure. The rising incidence of urinary tract cancer in countries like China, India, and Japan is driving the demand for advanced diagnostic and treatment solutions. Additionally, the growing presence of key pharmaceutical companies investing in oncology research and the introduction of cost-effective generic drugs are contributing to market expansion.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by advancements in precision medicine, rising adoption of immunotherapy, and increasing research investments. Additionally, a strong regulatory framework supporting fast-track drug approvals and reimbursement policies is boosting market growth. The increasing prevalence of urinary tract cancer due to aging populations and lifestyle-related risk factors is further driving demand for advanced therapies.

Key players in the market

Some of the key players in Urinary Tract Cancer Market include Amgen Inc., AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genzyme Corporation, IkerChem S.L, Kyowa Hakko Kirin Co, Medical Enzymes AG, Merck & Co Inc, Novartis AG , Pfizer Inc, Shionogi & Co., Ltd, Spectrum Pharmaceuticals, Exact Sciences and ImmunityBio, Inc.

Key Developments:

In March 2024, Exact Sciences launched Cxbladder Trio, a non-invasive urine-based genomic test for detecting upper tract urothelial cancer (UTUC). The test combines mRNA biomarkers and clinical risk factors, offering 92% sensitivity in early-stage diagnosis, per clinical validation studies.

In April 2024, ImmunityBio, Inc. announced that the U.S. FDA approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guerin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). This approval introduces a novel immunotherapy option enhancing treatment outcomes for bladder cancer patients.

Cancer Types Covered:

  • Bladder Cancer
  • Urethral Cancer
  • Ureteric & Renal Pelvic Cancer

Diagnostic Techniques Covered:

  • Cystoscopy
  • Transurethral Resection of Tumor
  • Imaging Tests
  • Urine Analyses
  • Other Diagnostic Techniques

Treatments Covered:

  • Chemotherapy
  • Intravesical Therapy
  • Radiation Therapy
  • Surgery
  • Immunotherapy

End Users Covered:

  • Hospitals
  • Speciality Clinics
  • Ambulatory Surgical Centers
  • Cancer Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Urinary Tract Cancer Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Bladder Cancer
    • 5.2.1 Transitional Cell Carcinoma
    • 5.2.2 Squamous Cell Carcinoma
    • 5.2.3 Adenocarcinoma
  • 5.3 Urethral Cancer
  • 5.4 Ureteric & Renal Pelvic Cancer

6 Global Urinary Tract Cancer Market, By Diagnostic Technique

  • 6.1 Introduction
  • 6.2 Cystoscopy
  • 6.3 Transurethral Resection of Tumor
  • 6.4 Imaging Tests
  • 6.5 Urine Analyses
  • 6.6 Other Diagnostic Techniques

7 Global Urinary Tract Cancer Market, By Treatment

  • 7.1 Introduction
  • 7.2 Chemotherapy
  • 7.3 Intravesical Therapy
  • 7.4 Radiation Therapy
  • 7.5 Surgery
  • 7.6 Immunotherapy

8 Global Urinary Tract Cancer Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Speciality Clinics
  • 8.4 Ambulatory Surgical Centers
  • 8.5 Cancer Research Institutes

9 Global Urinary Tract Cancer Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Amgen Inc.
  • 11.2 AstraZeneca
  • 11.3 Boehringer Ingelheim GmbH
  • 11.4 Bristol-Myers Squibb Company
  • 11.5 Eli Lilly and Company
  • 11.6 F. Hoffmann-La Roche Ltd
  • 11.7 Genzyme Corporation
  • 11.8 IkerChem S.L
  • 11.9 Kyowa Hakko Kirin Co
  • 11.10 Medical Enzymes AG
  • 11.11 Merck & Co Inc
  • 11.12 Novartis AG
  • 11.13 Pfizer Inc
  • 11.14 Shionogi & Co., Ltd
  • 11.15 Spectrum Pharmaceuticals
  • 11.16 Exact Sciences
  • 11.17 ImmunityBio, Inc

List of Tables

  • Table 1 Global Urinary Tract Cancer Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Urinary Tract Cancer Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 3 Global Urinary Tract Cancer Market Outlook, By Bladder Cancer (2024-2032) ($MN)
  • Table 4 Global Urinary Tract Cancer Market Outlook, By Transitional Cell Carcinoma (2024-2032) ($MN)
  • Table 5 Global Urinary Tract Cancer Market Outlook, By Squamous Cell Carcinoma (2024-2032) ($MN)
  • Table 6 Global Urinary Tract Cancer Market Outlook, By Adenocarcinoma (2024-2032) ($MN)
  • Table 7 Global Urinary Tract Cancer Market Outlook, By Urethral Cancer (2024-2032) ($MN)
  • Table 8 Global Urinary Tract Cancer Market Outlook, By Ureteric & Renal Pelvic Cancer (2024-2032) ($MN)
  • Table 9 Global Urinary Tract Cancer Market Outlook, By Diagnostic Technique (2024-2032) ($MN)
  • Table 10 Global Urinary Tract Cancer Market Outlook, By Cystoscopy (2024-2032) ($MN)
  • Table 11 Global Urinary Tract Cancer Market Outlook, By Transurethral Resection of Tumor (2024-2032) ($MN)
  • Table 12 Global Urinary Tract Cancer Market Outlook, By Imaging Tests (2024-2032) ($MN)
  • Table 13 Global Urinary Tract Cancer Market Outlook, By Urine Analyses (2024-2032) ($MN)
  • Table 14 Global Urinary Tract Cancer Market Outlook, By Other Diagnostic Techniques (2024-2032) ($MN)
  • Table 15 Global Urinary Tract Cancer Market Outlook, By Treatment (2024-2032) ($MN)
  • Table 16 Global Urinary Tract Cancer Market Outlook, By Chemotherapy (2024-2032) ($MN)
  • Table 17 Global Urinary Tract Cancer Market Outlook, By Intravesical Therapy (2024-2032) ($MN)
  • Table 18 Global Urinary Tract Cancer Market Outlook, By Radiation Therapy (2024-2032) ($MN)
  • Table 19 Global Urinary Tract Cancer Market Outlook, By Surgery (2024-2032) ($MN)
  • Table 20 Global Urinary Tract Cancer Market Outlook, By Immunotherapy (2024-2032) ($MN)
  • Table 21 Global Urinary Tract Cancer Market Outlook, By End User (2024-2032) ($MN)
  • Table 22 Global Urinary Tract Cancer Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 23 Global Urinary Tract Cancer Market Outlook, By Speciality Clinics (2024-2032) ($MN)
  • Table 24 Global Urinary Tract Cancer Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 25 Global Urinary Tract Cancer Market Outlook, By Cancer Research Institutes (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.